Search results
Results From The WOW.Com Content Network
Dec. 2—Pfizer Inc. is starting to roll out the pharmaceutical company's biggest round of layoffs since 2009, and its Groton laboratories are not immune. Of course, New York-based Pfizer these ...
In April 2023, Viatris was recognized by LinkedIn as one of the 25 best companies to work for in India, [21] and one of the 25 best companies offering career development in Ireland. [22] In May 2023, USA Today included Viatris in its list of 400 US companies that have reduced their greenhouse gas emissions intensity from 2019 to 2021. [23]
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
In all, more than 1,000 tech companies announced cuts of almost 160,000 jobs last year, according to the tracking website Layoffs.fyi. And nearly 100,000 more jobs already have been tagged this year.
Donald Trump's Agenda 47 and the Heritage Foundation's Project 2025 provide plenty of clues into what health-care changes may be coming. ... “the FDA should prohibit pharmaceutical companies ...
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company.Headquartered in Princeton, New Jersey, [2] BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
The two companies had agreed to a $54 billion deal that would allow AbbVie to move its headquarters overseas to Europe, reducing their corporate tax rate. However, the U.S. Treasury passed laws, tightening down on tax inversion deals just before the merger was completed, making the agreement much less profitable for AbbVie.